Vanda Pharmaceuticals Inc. and OliPass Corp. have entered into a research and development collaboration to jointly develop a set of antisense oligonucleotide (ASO) molecules based on OliPass’ modified peptide nucleic acids. The partnership leverages the respective strengths of Vanda and OliPass to support the development of ASO-based precision medicine therapeutics and potentially create compelling value opportunities for both companies.
 
The collaboration will focus on editing and modifying gene expression using ASOs in disease states where the expression of genes is either altered or the sequence of the expressed genes can be altered for therapeutic benefit. Olipass’ Peptide Nucleic Acids (OPNA) technology provides the delivery platform to enable these gene expression modifications.
 
“We are excited to have a partner to enhance our antisense oligonucleotide program platform aimed at the treatment of disorders with well-understood genetic mechanisms and for which there is a high unmet medical need,” said Mihael H. Polymeropoulos, M.D., Vanda’s President, CEO and Chairman of the Board. “Olipass’ delivery platform holds the promise of efficient delivery of our ASO’s in pursuit of the development of precision therapeutics.”
 
“Vanda shares a vision with us on the potential for anti-sense oligonucleotides to open up a broad range of therapeutic options to patients,” said Dr. Shin Chung, CEO of OliPass. “We look forward to working together to enhance the therapeutic profile of these molecules and playing an integral role in bringing them into the clinical setting.”
 
Vanda has already identified two ASO targets that have been validated in cell lines that model two undisclosed disease targets, one rare orphan and the other applicable to a broad set of immuno-oncological conditions. Vanda’s partnership with OliPass aims to enhance the existing ASOs with OliPass’ unique OPNA chemistry is the next step to take these preclinical findings to in vivo and clinical testing.